A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review

A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review

Context and Objectives: Interferon Beta (IFNβ) is a well-established first-line treatment for patients with multiple sclerosis (RRMS) and remains the most represented agent in sclerosis. Atypical hemolytic uremic syndrome (AHUS) represents a rare but serious adverse effect (AE) that can occur even after many years from the beginning of IFNβ therapy. ECULIZUMAB is currently approved for the treatment of Ahus and recently for the NEUROMYELITE OPTICA SPECTRUM SPECTRUM (NMOSD) with Aquaporin-4 antibodies (AQP4-IGG). In this article, we report the case of the appearance of IFNβ-related IFNβ experienced by an MS patient and we briefly examine the literature on this subject.

Methods: We conducted a systematic review of literature using PubMed and we conducted a retrospective analysis of RRMS patients who received IFNβ-1A in our center and developed thrombotic microangiopathy (TMA). From this search, we have identified only one patient.
Results: In the published literature, we have identified 24 member patients who have received the IFNβ as a treatment modifying the disease (DMT), then developed thrombotic microangiopathy with kidney injury. The Ahus was diagnosed in 6, all IFNβ-1a received and the last appearance was after 15 years. We report a case of a 39-year-old man who has assumed IFNβ-1A since 1999. In July 2018, he has developed an Ahus related to IFNβ. After the failure of the plasma exchange, it has undergone an Eculizumab, with an improvement in the glomerular filtration rate and without new signs of MS activity.

Conclusion: To our knowledge, this case represents the last appearance of IFNβ-related Ahus in patients with SEP. So far, there are no literary reports on the possibility of reintroducing a DMT as a complementary therapy to Eculizumab.

 

Effectiveness of interferon pegylated monotherapy in the treatment of chronic infection of virus hepatitis: a meta-analysis

An HDV chronic infection is often associated with an aggressive form of liver disease with respect to chronic mono-infection of HBV. However, chronic HDV treatment is difficult because there is currently no approved scheme for affected patients. While standard interferon with / without nucleos (t) IDE analogs were lower than pegylated interferon (peginterferon) as HDV treatment based on some randomized clinical trials. This meta-analysis will summarize the results of studies on the effectiveness of peginterferon as an HDV treatment plan. An electronic search was performed using PubMed databases, Cochrane Library, Research Door and Medline.

Studies involving patients who received peginterfer therapy for at least 48 weeks and followed for 24 weeks after therapy were included. All analyzes were conducted using Review Manager 5.3 designed for Cochrane Critics. The main efficiency endpoint was the virological response (VR) or HDV-RNA negativity at the end of the tracking period, while the endpoints of secondary efficiency were a biochemical response (BR or a clearance of ALT and an HBSAG authorization with seroconversion at the end of the follow-up period. The data has been summarized by 13 relevant studies with a total of 475 patients treated with PEGINTERFERON ALPHA-2A or -2B.

At the end of the post-treatment of 24 weeks, the grouped RV was carried out in 29% of patients with 95% of CI [24%; 34%], BR was reached in 33% of patients [95% CI 27%; 40%] and HBSAC clearance with anti-HBS seroconversion was obtained in 1% of patients with 95% CI [-0.02; 0.05]. In conclusion, this study showed that peginterferon has limited efficacy in HDV treatment, since a third of patients with chronic HDV reached viral clearance and standard Alt levels. In addition, HBSAG clearance with anti-HBS seroconversion has rarely been observed in patients with chronic HDV.

 A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review
A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review

New perspectives on the persistence of hepatitis D: the role of the response of interferon and implications for future therapies

Chronic Hepatitis (CHD), a global health problem, manifests itself as the most serious form of viral hepatitis. The causative agent, the hepatitis D virus (HDV), is the smallest known human virus reproduces its RNA genome with a circular slide in the hepatocyte core. HDV requires hepatitis B virus coded envelope proteins (HBV) for diffusion and NOVO cell input. However, HDV can also spread through cell division. After the NTCP mediated input in hepatocytes, the replica intermediates of HDV RNA are detected by the MDA5 pattern recognition receiver, resulting in an induction IFN-β / λ. This response from the IFN strongly suppresses the spread of HDV genomes with mediation by cell division, but only slightly affects RNA replication HDV in hepatocytes already infected, at rest. In patients, the mono-therapy with IFN-α / λ shows efficiency but rarely leads to an HDV authorization.

Recent molecular information on key determinants of HDV persistence and accelerated development of specifically acting antivirals interfering with the replication cycle, opens a new promising therapeutic perspective. In this report, we soon summarize our knowledge about the replication / persistence of HDV and newly discovered HDV agents, HDV interaction with IFN response and its consequences for persistence. Finally, we discuss the possible role of IFNS in combination with new upcoming therapies for HDV healing. Multiple sclerosis (MS) is an inflammatory self-immunoum disorder in the human central nervous system. The recombinant beta interferon (IFN-β) decreases the number of relapses and repels the progression of the disability of the sp.

cDNA - Human Tumor Cell Line: Raji

C1255840 40 reactions
EUR 424

Total RNA - Human Tumor Cell Line: Raji

R1255840-50 50 ug
EUR 229

FFPE Genomic DNA - Human Tumor Tissue: Lung

D2235152 2 ug
EUR 1104

FFPE Genomic DNA - Human Tumor Tissue: Colon

D2235090 2 ug
EUR 1104

Total Protein - Human Tumor Cell Line: Raji

P1255840 1 mg
EUR 216

FFPE Genomic DNA - Human Tumor Tissue: Breast

D2235086 2 ug
EUR 1104

FFPE Genomic DNA - Human Tumor Tissue: Uterus

D2235274 2 ug
EUR 1104

FFPE Genomic DNA - Human Tumor Tissue: Stomach

D2235248 2 ug
EUR 1104

FFPE Genomic DNA - Human Tumor Tissue: Pancreas

D2235188 2 ug
EUR 1104

Membrane Protein - Human Tumor Cell Line: Raji

P3255840 0.1 mg
EUR 311

Genomic DNA - Human Tumor Tissue: Lung Tumor, from a single donor

D1235152 50 ug
EUR 562

Genomic DNA - Human Tumor Tissue: Colon Tumor, from a single donor

D1235090 50 ug
EUR 562

Genomic DNA - Human Tumor Tissue: Liver Tumor, from a single donor

D1235149 50 ug
EUR 562

Genomic DNA - Human Tumor Tissue: Ovary Tumor, from a single donor

D1235183 50 ug
EUR 562

Genomic DNA - Human Tumor Tissue: Breast Tumor, from a single donor

D1235086 50 ug
EUR 562

Genomic DNA - Human Tumor Tissue: Kidney Tumor, from a single donor

D1235142 50 ug
EUR 562

Genomic DNA - Human Tumor Tissue: Rectum Tumor, from a single donor

D1235206 50 ug
EUR 562

Genomic DNA - Human Tumor Tissue: Uterus Tumor, from a single donor

D1235274 50 ug
EUR 562

Genomic DNA - Human Tumor Tissue: Stomach Tumor, from a single donor

D1235248 50 ug
EUR 562

Genomic DNA - Human Tumor Tissue: Thyroid Tumor, from a single donor

D1235265 50 ug
EUR 562

Genomic DNA - Human Tumor Tissue: Esophagus Tumor, from a single donor

D1235106 50 ug
EUR 562

96 Well Lung Tumor Genomic DNA Plate

D8235152-1 1 plate
EUR 377

96 Well Colon Tumor Genomic DNA Plate

D8235090-1 1 plate
EUR 377

96 Well Breast Tumor Genomic DNA Plate

D8235086-1 1 plate
EUR 377

96 Well Stomach Tumor Genomic DNA Plate

D8235248-1 1 plate
EUR 377

FFPE and Frozen Matched Pair Genomic DNA: Human Tumor Tissue: Lung

D8235152-FP 2 x 2 ug
EUR 2730

FFPE and Frozen Matched Pair Genomic DNA: Human Tumor Tissue: Colon

D8235090-FP 2 x 2 ug
EUR 2730

FFPE and Frozen Matched Pair Genomic DNA: Human Tumor Tissue: Breast

D8235086-FP 2 x 2 ug
EUR 2730

FFPE and Frozen Matched Pair Genomic DNA: Human Tumor Tissue: Stomach

D8235248-FP 2 x 2 ug
EUR 2898

Human Genomic DNA

BIO-35025 500µl @ 200ng/µl Ask for price

Human Genomic DNA

PCR-261 20µg
EUR 96

Human Genomic DNA 

X11000
  • Ask for price
  • Ask for price
  • 0.2 ml
  • 0.2 ml

Human Genomic DNA, male

GH-180M 0.1mg
EUR 177

Human Skin Genomic DNA

HG-101 0.05mg
EUR 210

Human Lung Genomic DNA

HG-601 0.05mg
EUR 210

Human Brain Genomic DNA

HG-201 0.05mg
EUR 210

Human Colon Genomic DNA

HG-311 0.05mg
EUR 210

Human Liver Genomic DNA

HG-314 0.05mg
EUR 210

Human Blood Genomic DNA

HG-705 0.05mg
EUR 319

Human Heart Genomic DNA

HG-801 0.05mg
EUR 210

Human Brain Genomic DNA  

X11001
  • Ask for price
  • Ask for price
  • 10 µg
  • 10 ul

Human Genomic DNA, female

GH-180F 0.1mg
EUR 177

Human Testis Genomic DNA

HG-401 0.05mg
EUR 210

Human Uterus Genomic DNA

HG-411 0.05mg
EUR 210

Human Spleen Genomic DNA

HG-701 0.05mg
EUR 210

Human Thymus Genomic DNA

HG-702 0.05mg
EUR 210

Human Kidney Genomic DNA

HG-901 0.05mg
EUR 210

Human Stomach Genomic DNA

HG-302 0.05mg
EUR 210

Human Pancreas Genomic DNA

HG-313 0.05mg
EUR 210

Human Placenta Genomic DNA

HG-413 0.05mg
EUR 210

Human Esophagus Genomic DNA

HG-301 0.05mg
EUR 210

Human Intestine Genomic DNA

HG-306 0.05mg
EUR 210

Control Genomic DNA - Human Male

D1234999-G01 100 ug
EUR 196

Mammalian Cell Genomic DNA Isolation Kit

K967-100 each
EUR 457.2

Control Genomic DNA - Human Female

D1234999-G02 100 ug
EUR 196

Genomic DNA Mini Kit (Blood/Cultured Cell)

GB004 each
EUR 3

Genomic DNA Mini Kit (Blood/Cultured Cell)

GB100 each
EUR 70

Genomic DNA Mini Kit (Blood/Cultured Cell)

GB300 each
EUR 189

Genomic DNA Maxi Kit (Blood/Cultured Cell)

GDM002 each
EUR 21

Genomic DNA Maxi Kit (Blood/Cultured Cell)

GDM010 each
EUR 89.3

Genomic DNA Maxi Kit (Blood/Cultured Cell)

GDM025 each
EUR 199.5

Magnetic bead Blood/Cell Genomic DNA Kit

PDM06-0100 100 rcs
EUR 265

Human Spinal Cord Genomic DNA

HG-230 0.05mg
EUR 210

Human Bone Marrow Genomic DNA

HG-704 0.05mg
EUR 319

Insta NX® Cell Genomic DNA Purification

MBIN011-12PR 1 unit
EUR 71.73
Description: Insta NX® Cell Genomic DNA Purification

Raji Cell Line

CL-0189 1×10⁶ cells/vial
EUR 420
Description: Homo sapiens, Human

Human Skeletal Muscles Genomic DNA

HG-102 0.05mg
EUR 210

Cat Genomic DNA

GC-130 0.1mg
EUR 177

Genomic DNA Kit

20-abx098076
  • Ask for price
  • Ask for price
  • 200 rxns
  • 50 rxns

ELK Genomic DNA

GE-240 0.1mg
EUR 177

Fig Genomic DNA

PLG-1042 0.1mg
EUR 307

Oat Genomic DNA

PLG-1096 0.1mg
EUR 307

Rye Genomic DNA

PLG-1097 0.1mg
EUR 307

Pea Genomic DNA

PLG-1141 0.1mg
EUR 307

GENOMIC DNA KIT

IB47250 2 X 96 PREP KIT
EUR 759.68

GENOMIC DNA KIT

IB47251 4 X 96 PREP KIT
EUR 1464.04

GENOMIC DNA KIT

IB47252 10 X 96 PREP KIT
EUR 3254.61

Genomic DNA Kit

abx098076-100l 100 µl
EUR 300

Genomic DNA Kit

abx098076-1ml 1 ml Ask for price

Genomic DNA Kit

abx098076-200l 200 µl
EUR 550

Crab Genomic DNA

GRA-340 0.025mg
EUR 177

Goat Genomic DNA

GG-150 0.1mg
EUR 177

Clam Genomic DNA

GCL-325 0.025mg
EUR 177

Duck Genomic DNA

GD-220 0.1mg
EUR 177

Corn Genomic DNA

PLG-1002 0.1mg
EUR 307

Rice Genomic DNA

PLG-1004 0.1mg
EUR 307

Pear Genomic DNA

PLG-1033 0.1mg
EUR 307

Pork Genomic DNA

PCR-705 20µg
EUR 90.1

Quail Genomic DNA

GQ-200 0.1mg
EUR 177

Squid Genomic DNA

GSQ-380 0.025mg
EUR 177

Camel Genomic DNA

GC-270 0.1mg
EUR 177

Goose Genomic DNA

GG-140 0.1mg
EUR 177

Ecoli Genomic DNA*

GE-310 0.05mg
EUR 177

Llama genomic DNA

GL-260 0.1mg
EUR 177

Yeast Genomic DNA*

GY-300 0.05mg
EUR 177

Apple Genomic DNA

PLG-1001 0.1mg
EUR 307

Beans Genomic DNA

PLG-1051 0.1mg
EUR 307

Lemon Genomic DNA

PLG-1062 0.1mg
EUR 307

Wheat Genomic DNA

PLG-1084 0.1mg
EUR 307

Onion Genomic DNA

PLG-1092 0.1mg
EUR 307

Maple Genomic DNA

PLG-1094 0.1mg
EUR 307

Lotus Genomic DNA

PLG-1161 0.1mg
EUR 307

Horse Genomic DNA

PCR-706 20µg
EUR 90.1

Oyster Genomic DNA

GOY-330 0.025mg
EUR 177

Pigeon Genomic DNA

GP-210 0.1mg
EUR 177

Turkey Genomic DNA

GT-150 0.1mg
EUR 177

Alpaca Genomic DNA

GAP-260 0.1mg
EUR 177

Ferret Genomic DNA*

GF-180 0.05mg
EUR 177

Gerbil Genomic DNA*

GG-120 0.05mg
EUR 177

Shirmp Genomic DNA

GHR-375 0.025mg
EUR 177

Donkey Genomic DNA

GD-160 0.1mg
EUR 177

Orange Genomic DNA

PLG-1003 0.1mg
EUR 307

Cotton Genomic DNA

PLG-1022 0.1mg
EUR 307

Banana Genomic DNA

PLG-1031 0.1mg
EUR 307

Barley Genomic DNA

PLG-1041 0.1mg
EUR 307

Pepper Genomic DNA

PLG-1043 0.1mg
EUR 307

Potato Genomic DNA

PLG-1073 0.1mg
EUR 307

Tomato Genomic DNA

PLG-1074 0.1mg
EUR 307

Carrot Genomic DNA

PLG-1081 0.1mg
EUR 307

Radish Genomic DNA

PLG-1083 0.1mg
EUR 307

Cherry Genomic DNA

PLG-1091 0.1mg
EUR 307

Squash Genomic DNA

PLG-1111 0.1mg
EUR 307

Lentil Genomic DNA

PLG-1151 0.1mg
EUR 307

Ostrich Genomic DNA

GO-320 0.1mg
EUR 177

Catfish Genomic DNA

GFC-190 0.025mg
EUR 177

Lobster Genomic DNA

GLB-370 0.025mg
EUR 177

Mussels Genomic DNA

GMU-345 0.025mg
EUR 177

Apricot Genomic DNA

PLG-1011 0.1mg
EUR 307

Soybean Genomic DNA

PLG-1044 0.1mg
EUR 307

Spinach Genomic DNA

PLG-1054 0.1mg
EUR 307

Cabbage Genomic DNA

PLG-1071 0.1mg
EUR 307

Lettuce Genomic DNA

PLG-1072 0.1mg
EUR 307

Ginseng Genomic DNA

PLG-1088 0.05mg
EUR 307

However, up to 50% of patients treated with interferon beta are continuing to live relapses and / or aggravate disability. Simple nucleotide polymorphisms of different genes have been known to show significant associations with a response to IFN-β in patients with SEP. In the current work, we examined the potential role of the genes of TrainR1 and GRIA3 genes on the response to IFN-β therapy in patients with Iranian MS. The DNA was extracted from blood samples with standard procedures of 73 patients diagnosed with multiple sclerosis that were responded to IFN-β or not.

Leave A Comment